Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death
- PMID: 20920357
- PMCID: PMC2958942
- DOI: 10.1186/1471-2407-10-526
Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death
Abstract
Background: Glycogen Synthase Kinase-3 (GSK-3) α and β are two serine-threonine kinases controlling insulin, Wnt/β-catenin, NF-κB signaling and other cancer-associated transduction pathways. Recent evidence suggests that GSK-3 could function as growth-promoting kinases, especially in malignant cells. In this study, we have investigated GSK-3α and GSK-3β function in multiple myeloma (MM).
Methods: GSK-3 α and β expression and cellular localization were investigated by Western blot (WB) and immunofluorescence analysis in a panel of MM cell lines and in freshly isolated plasma cells from patients. MM cell growth, viability and sensitivity to bortezomib was assessed upon treatment with GSK-3 specific inhibitors or transfection with siRNAs against GSK-3 α and β isoforms. Survival signaling pathways were studied with WB analysis.
Results: GSK-3α and GSK-3β were differently expressed and phosphorylated in MM cells. Inhibition of GSK-3 with the ATP-competitive, small chemical compounds SB216763 and SB415286 caused MM cell growth arrest and apoptosis through the activation of the intrinsic pathway. Importantly, the two inhibitors augmented the bortezomib-induced MM cell cytotoxicity. RNA interference experiments showed that the two GSK-3 isoforms have distinct roles: GSK-3β knock down decreased MM cell viability, while GSK-3α knock down was associated with a higher rate of bortezomib-induced cytotoxicity. GSK-3 inhibition caused accumulation of β-catenin and nuclear phospho-ERK1, 2. Moreover, GSK-3 inhibition and GSK-3α knockdown enhanced bortezomib-induced AKT and MCL-1 protein degradation. Interestingly, bortezomib caused a reduction of GSK-3 serine phosphorylation and its nuclear accumulation with a mechanism that resulted partly dependent on GSK-3 itself.
Conclusions: These data suggest that in MM cells GSK-3α and β i) play distinct roles in cell survival and ii) modulate the sensitivity to proteasome inhibitors.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2958942/bin/1471-2407-10-526-1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2958942/bin/1471-2407-10-526-2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2958942/bin/1471-2407-10-526-3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2958942/bin/1471-2407-10-526-4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2958942/bin/1471-2407-10-526-5.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2958942/bin/1471-2407-10-526-6.gif)
Similar articles
-
Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner.J Biol Chem. 2013 Nov 8;288(45):32777-32786. doi: 10.1074/jbc.M113.480921. Epub 2013 Oct 1. J Biol Chem. 2013. PMID: 24085292 Free PMC article.
-
Dual alterations in casein kinase I-epsilon and GSK-3beta modulate beta-catenin stability in hyperproliferating colonic epithelia.Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G599-607. doi: 10.1152/ajpgi.00343.2006. Epub 2006 Oct 19. Am J Physiol Gastrointest Liver Physiol. 2007. PMID: 17053159
-
[Proteasome inhibitors sensitize ovarian cancer cells to paclitaxel induced apoptosis].Zhonghua Fu Chan Ke Za Zhi. 2008 Oct;43(10):770-3. Zhonghua Fu Chan Ke Za Zhi. 2008. PMID: 19087546 Chinese.
-
Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer.Semin Cancer Biol. 2019 Jun;56:25-36. doi: 10.1016/j.semcancer.2017.12.010. Epub 2018 Jan 5. Semin Cancer Biol. 2019. PMID: 29309927 Review.
-
Association of glycogen synthase kinase-3β with Parkinson's disease (review).Mol Med Rep. 2014 Jun;9(6):2043-50. doi: 10.3892/mmr.2014.2080. Epub 2014 Mar 28. Mol Med Rep. 2014. PMID: 24681994 Free PMC article. Review.
Cited by
-
Progranulin Protects against Hyperglycemia-Induced Neuronal Dysfunction through GSK3β Signaling.Cells. 2023 Jul 7;12(13):1803. doi: 10.3390/cells12131803. Cells. 2023. PMID: 37443837 Free PMC article.
-
Developing mRNA signatures as a novel prognostic biomarker predicting high risk multiple myeloma.Front Oncol. 2023 Feb 23;13:1105196. doi: 10.3389/fonc.2023.1105196. eCollection 2023. Front Oncol. 2023. PMID: 36910651 Free PMC article.
-
Glycogen Synthase Kinase 3β: A True Foe in Pancreatic Cancer.Int J Mol Sci. 2022 Nov 16;23(22):14133. doi: 10.3390/ijms232214133. Int J Mol Sci. 2022. PMID: 36430630 Free PMC article. Review.
-
CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma.Cancers (Basel). 2022 Aug 29;14(17):4173. doi: 10.3390/cancers14174173. Cancers (Basel). 2022. PMID: 36077711 Free PMC article.
-
Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma.Front Cell Dev Biol. 2022 Aug 11;10:935023. doi: 10.3389/fcell.2022.935023. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36035991 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous